Products Porfolio &
LAI Opportunities

 
 

Fast expanding portfolio

Already 5 programs in Preclinical & Clinical

Our pipeline

LEAD FORMULATION RESEARCH

mdc-WWM
CONTRACEPTION
PARTNER: BILL & MELINDA GATES FOUNDATION
mdc-NVA
PAIN
mdc-GRT
ORGAN TRANSPLANT
mdc-DOM
UROLOGY

PRECLINICAL & CLINICAL DEVELOPMENT

mdc-IRM
SCHIZOPHRENIA
PARTNER: TEVA

mdc-IRM / Schizophrenia • Clinical Phase 3

mdc-TJK
Central Nervous System
PARTNER: TEVA

mdc-TJK / CNS • Preclinical & Regulatory

mdc-CWM
PAIN AND INFLAMMATION
PARTNER: AIC

mdc-CWM / Pain & Inflammation • Clinical Phase 2

mdc-CMV /
ANESTHESIA, PAIN
Internal

mdc-CMV / Anesthesia, Pain • Preclinical & Regulatory

mdc-ANG
CNS
Partner: TEVA

mdc-ANG / CNS • Preclinical & Regulatory

As of July, 2019

Favorable risk assessment

All current products under development are based on already approved APIs. When compared to NCEs (New Chemical Entity), use of well-understood, approved APIs is an opportunity to make treatments quickly available with significantly less financial resources needed and less risk in clinical phases.

 

LAI Opportunities

Identification

We have designed a structured approach to identify LAI opportunities and enlarge our portfolio of proprietary and partnered products. This assessment process aims to identify the unmet needs in a large panel of indications that could be met with LAI and to identify the most compatible APIs with our technology. This preliminary step is essential to significantly increase the likelihood of success for each product entering formulation stage.

 
 

Opportunities
with approved APIs


Products based on already approved APIs can benefit from decreased time-to-market thanks to simplified pathways such as the 505(b)2 in the US, while providing all of the benefits from long-acting formulations with controlled release.

Opportunities
with new APIs

There is a significant number of new therapeutic molecules that could be optimized for long-acting injectable treatments. Our technology could be the empowering entity to APIs that can’t be used in today’s traditional, drug delivery systems, or whose benefits would be limited as a result of toxicity.

We’re always looking for new talent

See our career opportunities

CONTACT

  • This field is for validation purposes and should be left unchanged.